Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott’s D2E7 is Humira

Executive Summary

Abbott selects Humira as trade name for tumor necrosis factor inhibitor D2E7/adalimumab. Abbott submitted a BLA for rheumatoid arthritis April 2 and expects to launch in the first half of 2003. Humira will be the first product manufactured at Abbott's biotech plant in Barceloneta, Puerto Rico upon completion of the $350 mil. facility. Abbott also recently expanded its bioresearch center in Worcester, Mass. (1"The Pink Sheet" Oct. 14, p. 27)...
Advertisement

Related Content

Abbott D2E7 Patient Rollover From Access Program Will Follow Kaletra Model
Abbott D2E7 Patient Rollover From Access Program Will Follow Kaletra Model
Advertisement
UsernamePublicRestriction

Register

PS040707

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel